Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Dova Pharmaceuticals, Inc. (DOVA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/06/2019 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results"
05/07/2019 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results"
03/05/2019 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results DOPTELET ® approved May 21, 2018 and launched June 4, 2018 Net product sales from DOPTELET were $2.8 million in the fourth quarter of 2018 and $7.7 million for the full year ended December 31, 2018 sNDA accepted for review by FDA for DOPTELET for the treatment of chronic immune thrombocytopenia with a PDUFA goal date of June 30, 2019 Appointed Dr. David Zaccardelli as President and Chief Executive Officer and Jason Hoitt as Chief Commercial Officer Conference call scheduled for 9:00 a.m. ET today"
05/09/2018 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results"
02/15/2018 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy